Sign In
Get Clay Free →

Suggestions

    Luigi Manenti

    CMO at HiFiBiO Therapeutics

    Luigi Manenti is a physician and scientist with extensive experience in clinical oncology and drug development. He served as the Chief Medical Officer (CMO) at HiFiBiO Therapeutics from October 2021 to January 2023.12 During his tenure at HiFiBiO, Manenti led the clinical development organization, overseeing successful IND and CTA submissions and securing supply agreements for the investigational oncology drug tislelizumab.3

    Prior to his role at HiFiBiO, Manenti held several positions at major pharmaceutical companies:

    1. Team Leader for Solid Tumors in Novartis's Oncology Business Unit
    2. Executive Global Clinical Program Leader at Novartis Institutes for BioMedical Research (NIBR)
    3. Various roles at Roche in Switzerland and China

    Manenti's educational background includes an M.D. in Medicine and Surgery from the University of Pavia in Italy.1 He is a member of the American Society of Clinical Oncology (ASCO) and has authored several publications and patent applications.3

    As of January 2023, Luigi Manenti has taken on the role of Chief Medical Officer at Alentis Therapeutics, where he is responsible for leading the development of monoclonal antibodies targeting Claudin-1 (CLDN1) for the treatment of organ fibrosis and CLDN1+ tumors.2

    Related Questions

    What are Luigi Manenti's key achievements at HiFiBiO Therapeutics?
    How did Luigi Manenti contribute to the development of tislelizumab?
    What is Luigi Manenti's educational background?
    What are the main projects Luigi Manenti is working on at Alentis Therapeutics?
    How does Luigi Manenti's experience at Novartis compare to his roles at HiFiBiO and Alentis?
    Luigi Manenti
    Add to my network

    Location

    New York City Metropolitan Area